Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $25.00 target price on the stock.

Milestone Pharmaceuticals Price Performance

MIST traded up $0.31 on Monday, reaching $2.48. The company had a trading volume of 1,863,241 shares, compared to its average volume of 395,471. Milestone Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $2.75. The company has a market cap of $131.99 million, a price-to-earnings ratio of -3.05 and a beta of 1.83. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The business has a 50 day simple moving average of $2.02 and a 200 day simple moving average of $1.80.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp lifted its holdings in shares of Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after acquiring an additional 10,000 shares during the last quarter. National Bank of Canada FI lifted its stake in Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after purchasing an additional 11,600 shares during the last quarter. Atria Investments Inc lifted its stake in Milestone Pharmaceuticals by 44.4% in the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after purchasing an additional 12,430 shares during the last quarter. PVG Asset Management Corp bought a new position in shares of Milestone Pharmaceuticals during the third quarter valued at about $46,000. Finally, Northern Trust Corp grew its stake in shares of Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock valued at $137,000 after buying an additional 30,772 shares during the last quarter. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.